

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **May 2021**

Commission File Number: **001-39034**

**BELLUS HEALTH INC.**

---

*(Name of registrant)*

---

**275 Armand-Frappier Blvd.  
Laval, Québec  
H7V 4A7  
Canada**

---

*(Address of principal executive offices)*

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BELLUS Health Inc.**

Date: May 12, 2021

By: /s/ Ramzi Benamar

Name: Ramzi Benamar

Title: Chief Financial Officer

---

## Form 6-K Exhibit Index

Exhibit Number	Document Description
<a href="#">99.1</a>	<a href="#">News Release dated May 12, 2021. BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference.</a>



**BELLUS Health Inc.**  
275 Armand-Frappier Blvd.  
Laval, Quebec, Canada H7V 4A7

---

## **BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference**

LAVAL, Quebec—May 12, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference.

### **Presentation Details:**

**Event:** 2021 RBC Capital Markets Global Healthcare Conference

**Date/Time:** Wednesday, May 19, 2021 at 9:10 a.m. ET

A live webcast of fireside chat may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at [www.bellushealth.com](http://www.bellushealth.com). Following the event, an archived webcast will be available on the Company's website.

### **About BELLUS Health ([www.bellushealth.com](http://www.bellushealth.com))**

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough (“RCC”) and chronic pruritus associated with atopic dermatitis (“AD”).

RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and current treatment options are limited.

Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD, there continues to be a lack of options targeting the burden of pruritus in patients with AD.

### **FOR MORE INFORMATION, PLEASE CONTACT:**

Danny Matthews  
Director, Investor Relations and Communications  
[danny@bellushealth.com](mailto:danny@bellushealth.com)

### **Media:**

Julia Deutsch  
Solebury Trout  
[jdeutsch@soleburytrout.com](mailto:jdeutsch@soleburytrout.com)

Source: BELLUS Health Inc.